Tricida Inc (NASDAQ:TCDA) insider Gerrit Klaerner sold 5,826 shares of the business’s stock in a transaction dated Monday, July 8th. The shares were sold at an average price of $35.55, for a total transaction of $207,114.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
NASDAQ:TCDA opened at $33.23 on Friday. Tricida Inc has a 12 month low of $19.43 and a 12 month high of $42.80. The company has a 50-day moving average price of $36.29. The firm has a market capitalization of $1.66 billion and a price-to-earnings ratio of -7.16. The company has a debt-to-equity ratio of 0.24, a quick ratio of 8.30 and a current ratio of 8.30.
Tricida (NASDAQ:TCDA) last announced its earnings results on Wednesday, May 8th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.80) by ($0.10). Analysts expect that Tricida Inc will post -3.44 earnings per share for the current fiscal year.
A number of equities analysts have commented on TCDA shares. Empire boosted their price target on shares of Tricida from $37.00 to $58.00 in a research report on Monday, April 1st. Needham & Company LLC boosted their price target on shares of ViaSat from $78.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, May 24th. Zacks Investment Research lowered shares of Hollysys Automation Technologies from a “hold” rating to a “sell” rating in a research report on Thursday, April 11th. Cowen restated a “buy” rating and issued a $50.00 price target on shares of Tricida in a research report on Tuesday, June 25th. Finally, Goldman Sachs Group started coverage on shares of Tricida in a research report on Wednesday, June 26th. They issued a “buy” rating and a $48.00 price target on the stock. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $47.00.
Tricida, Inc, a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis.
Further Reading: Oversold
Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.